{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:03:48Z","timestamp":1788581028785,"version":"build-2803163510"},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2015]]},"DOI":"10.2169\/internalmedicine.54.3669","type":"journal-article","created":{"date-parts":[[2015,3,14]],"date-time":"2015-03-14T22:01:21Z","timestamp":1426370481000},"page":"591-595","source":"Crossref","is-referenced-by-count":18,"title":["Isoniazid-induced Acute Liver Failure during Preventive Therapy for Latent Tuberculosis Infection"],"prefix":"10.2169","volume":"54","author":[{"given":"Shoichi","family":"Miyazawa","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Hamana","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Nagai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Nirei","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiko","family":"Moriyama","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161: S221-S247, 2000.","DOI":"10.1164\/ajrccm.161.supplement_3.ats600"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Geng E, Kreiswirth B, Driver C, et al. Changes in the transmission of tuberculosis in New York City from 1990 to 1999. N Engl J Med 346: 1453-1458, 2002.","DOI":"10.1056\/NEJMoa012972"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Horsburgh CR Jr, Rubin EJ. Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med 364: 1441-1448, 2011.","DOI":"10.1056\/NEJMcp1005750"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Rose DN, Schechter CB, Silver AL. The age threshold for isoniazid chemoprophylaxis: a decision analysis for low-risk tuberculin reactors. JAMA 256: 2709-2713, 1986.","DOI":"10.1001\/jama.1986.03380190079029"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Comstock GW. Prevention tuberculosis among tuberculin reactors: maximizing benefits, minimizing risks. JAMA 256: 2729-2730, 1986.","DOI":"10.1001\/jama.1986.03380190099036"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Mochida S, Takikawa Y, Nakayama N, et al. Diagnostic criteria of acute liver failure: a report by the intractable hepato-biliary diseases study group of Japan. Hepatol Res 41: 805-812, 2011.","DOI":"10.1111\/j.1872-034X.2011.00860.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Fountain FF, Tolly E, Chrisman CR, et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 128: 116-123, 2005.","DOI":"10.1378\/chest.128.1.116"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Bass JB Jr, Fsrer LS, Hopewell PC, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med 149: 1359-1374, 1994.","DOI":"10.1164\/ajrccm.149.5.8173779"},{"key":"9","unstructured":"9. Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 117: 991-1001, 1978."},{"key":"10","unstructured":"10. Kunst H, Khan KS. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis 14: 1374-1381, 2010."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 157: 1871-1876, 1998.","DOI":"10.1164\/ajrccm.157.6.9711039"},{"key":"12","unstructured":"12. Bliven EE, Podewils LJ. The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection. Int J Tuberc Lung Dis 13: 1054-1060, 2009."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Bose PD, Sarma MP, Medhi S, et al. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterol Hepatol 26: 312-318, 2011.","DOI":"10.1111\/j.1440-1746.2010.06355.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Verma S, Kaplowitz N. Diagnosis, management and prevention of drug-induced liver injury. Gut 58: 1555-1564, 2009.","DOI":"10.1136\/gut.2008.163675"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Byrd RB, Horn BR, Griggs GA, et al. Isoniazid chemoprophylaxis: association with detection and incidence of liver toxicity. Arch Intern Med 137: 1130-1133, 1977.","DOI":"10.1001\/archinte.1977.03630210016007"},{"key":"16","unstructured":"16. Centers for Disease Control and Prevention. Severe isoniazid-associated hepatitis: New York, 1991-1993. MMWR Morb Mortal Wkly Rep 42: 545-547, 1993."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Khan FY, Rasoul F. Rifampicin-isoniazid induced fatal fulminant hepatitis during treatment of latent tuberculosis: a case report and literature review. Indian J Crit Care Med 14: 97-100, 2010.","DOI":"10.4103\/0972-5229.68226"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174: 935-952, 2006.","DOI":"10.1164\/rccm.200510-1666ST"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Sato S, Suzuki K, Takikawa Y, et al. Clinical epidemiology of fulminant hepatitis in Japan before the substantial introduction of liver transplantation: an analysis of 1309 cases in a 15-year national survey. Hepatol Res 30: 155-161, 2004.","DOI":"10.1016\/j.hepres.2004.08.003"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 27: 1266-1277, 1998.","DOI":"10.1086\/514993"},{"key":"21","unstructured":"21. Japanese Society for Tuberculosis. Response to hepatic dysfunction during treatment using antitubercular agents. Kekkaku (Tuberculosis) 82: 115-118, 2007 (in Japanese)."},{"key":"22","unstructured":"22. Nakazono T, Tezuka N, Tagawa H, et al. Liver dysfunction during treatment of latent tuberculosis infection. Kekkaku (Tuberculosis) 86: 51-55, 2011 (in Japanese, abstract in English)."},{"key":"23","unstructured":"23. Centers for Disease Control and Prevention. Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection: United States, 2004-2008. MMWR Morb Mortal Wkly Rep 59: 224-229, 2010."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T07:23:19Z","timestamp":1498202599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/6\/54_54.3669\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.54.3669","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}